Cold Genesys has raised $22 million in series C funding to advance its oncolytic immunotherapy for bladder cancer and other solid tumors. The biotech is developing the candidate both as a single agent ...

The evidence isn't there yet for routine use, but Michael Leapman, MD, urologic oncologist and associate professor of oncology at Yale School of Medicine, discusses what the future may hold for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bladder training is when a person makes a conscious effort to urinate at fixed intervals. The idea is to gradually increase those intervals over time. This could lead to a larger bladder capacity and ...